eIND submission for the PB004 project and further development of PB003G towards Phase 0

Pure Biologics submits an eIND application to the FDA for the start of Phase 0 in the PB004 project and decides on the further development of PB003G toward Phase 0.

News

Inquiries

Debut on the WSE Main Market, 14.12.2020 (on-line)

11 December

2020

Debut on the WSE Main Market, 14.12.2020 (on-line)

Pure Biologics debut on the Regulated Market of the Warsaw Stock Exchange.

25 November

2020

Filip Jeleń on “Parkiet TV”

The guest of Grzegorz Siemionczyk's #PROSTOzPARKIET program was Filip Jeleń, CEO of Pure Biologics.

Webinar organized by “Strefa Inwestorów” with Pure Biologics, Tuesday 24/11/2020

21 November

2020

Webinar organized by “Strefa Inwestorów” with Pure Biologics, Tuesday 24/11/2020

Webinar organized by "Strefa Inwestorów" with Pure Biologics, Tuesday 24/11/2020

“Nasz biznes zależy od ludzi i kapitału, a nie od miejsca” – Puls Biznesu article

19 November

2020

“Nasz biznes zależy od ludzi i kapitału, a nie od miejsca” – Puls Biznesu article

An interview with Filip Jeleń, Romuald Harwas and Przemysł Jurek.

13 November

2020

Antibody E-Conference 2020

On Friday, November 13, 2020 at 13:00 the Antibody E-conference 2020 took place.

Zapytanie Ofertowe – 00007/00008_ABM_01/2023

23 November

2023

Zapytanie Ofertowe – 00007/00008_ABM_01/2023

9 October

2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/5/20 09.10.2020

17 June

2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/4/20 17.06.2020

10 April

2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/3/20 10.04.2020

25 January

2020